Cargando…

Faecal Microbiota Transplantation, Paving the Way to Treat Non-Alcoholic Fatty Liver Disease

Non-alcoholic fatty liver disease (NAFLD) is currently the most prevalent cause of chronic liver disease (CLD). Currently, the only therapeutic recommendation available is a lifestyle change. However, adherence to this approach is often difficult to guarantee. Alteration of the microbiota and an inc...

Descripción completa

Detalles Bibliográficos
Autores principales: Del Barrio, María, Lavín, Lucía, Santos-Laso, Álvaro, Arias-Loste, Maria Teresa, Odriozola, Aitor, Rodriguez-Duque, Juan Carlos, Rivas, Coral, Iruzubieta, Paula, Crespo, Javier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10094628/
https://www.ncbi.nlm.nih.gov/pubmed/37047094
http://dx.doi.org/10.3390/ijms24076123
Descripción
Sumario:Non-alcoholic fatty liver disease (NAFLD) is currently the most prevalent cause of chronic liver disease (CLD). Currently, the only therapeutic recommendation available is a lifestyle change. However, adherence to this approach is often difficult to guarantee. Alteration of the microbiota and an increase in intestinal permeability seem to be key in the development and progression of NAFLD. Therefore, the manipulation of microbiota seems to provide a promising therapeutic strategy. One way to do so is through faecal microbiota transplantation (FMT). Here, we summarize the key aspects of FMT, detail its current indications and highlight the most recent advances in NAFLD.